DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recordings of the Earnings call conducted on October 27, 202328-10-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio Recordings of the Earnings call conducted on October 27, 2023DR.REDDY'S LABORATORIES LTD. - 500124 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015Dr. Reddy's Laboratories Results Earnings Call for Q2FY24
Conference Call with Dr. Reddy's Laboratories Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript.Dr Reddy's Q2 results: Net profit rises 33% to Rs 1,482 cr
Consolidated quarterly revenue rose 9% to Rs 6,903 crore led by a 9% growth in the key global generics segmentQ2FY24 Quarterly Result Announced for Dr. Reddy's Laboratories Ltd.
Pharmaceuticals company Dr. Reddy's Laboratories announced Q2FY24 results: Revenues of Rs 68,802 million, up 9% YoY and 2% QoQ. Gross Margin of 58.7%, compared to 59.1% in Q2FY23 and 57% in Q1FY24. SG&A; Expenses of Rs 18,795 million, up 13% YoY and 6% QoQ. R&D; Expenses of Rs 5,447 million, representing 7.9% of revenues. EBITDA of Rs 21,813 million, accounting for 31.7% of revenues. Profit before Tax of Rs 19,134 million, up 19% YoY and 4% QoQ. Profit after Tax of Rs 14,800 million, up 33% YoY and 6% QoQ. Commenting on the results, Co-Chairman & MD, G V Prasad said, "We delivered another quarter of strong results with highest ever sales and profits, driven by market share gains & momentum in our US generics business and robust growth in Europe. We are continuing to strengthen our pipeline both organically and through business development to drive growth and create differentiation." Result PDFDR.REDDY'S LABORATORIES LTD. - 500124 - Unaudited Financial Results For The Quarter And Half-Year Ended September 30, 2023
Unaudited Financial results for the quarter and half-year ended September 30, 2023DR.REDDY'S LABORATORIES LTD. - 500124 - Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half-Year Ended September 30, 2023
Outcome of Board Meeting - Unaudited Financial Results for the quarter and half-year ended September 30, 2023DR.REDDY'S LABORATORIES LTD. - 500124 - Grant Of Employee Stock Options
Grant of Employee Stock optionsDr Reddy Share Price Live blog for 20 Oct 2023
Dr Reddy stock price went down today, 20 Oct 2023, by -0.9 %. The stock closed at 5675.85 per share. The stock is currently trading at 5624.5 per share. Investors should monitor Dr Reddy stock price closely in the coming days and weeks to see how it reacts to the news.